Related Experiment Video
Updated: Jul 8, 2025
CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells
Published on: June 2, 2022
E2F5 Targeted by Let-7d-5p Facilitates Cell Proliferation, Metastasis and Immune Escape in Gallbladder Cancer
Lei Chen1, Songyi Guo1, Dafang Zhang1
1Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, 100044, China.
Background:
Gallbladder cancer (GBC) remains a serious cause of cancer-related mortality across the globe. E2F5 has been identified to as a known oncogene in various cancers. However, the special functions of E2F5 have not been investigated in GBC.
Aims:
To explore the regulatory functions of E2F5 and its related molecular regulatory mechanism in GBC progression.
Methods:
The expression of genes were examined through qRT-PCR, western blot and IHC assay. The cell proliferation was assessed through CCK-8 and EDU assays. The cytotoxicity was tested through LDH assay. The percentage of CD8+ T cells and cell apoptosis were evaluated through flow cytometry. The binding ability was detected through luciferase reporter assay. The tumor growth was assessed through in vivo assays.
Results:
In this study, it was demonstrated that E2F5 expression was evaluated in GBC, and resulted into poor prognosis. Bioinformatics analysis revealed E2F5 as a target for let-7d-5p, which when overexpressed, suppressed the metastasis and proliferation of GBC through the downregulation of E2F5. It was discovered that E2F5 activates JAK2/STAT3 signaling which is suppressed by let-7d-5p, implicating this pathway as one of the effectors of the oncogenic effects of ESF5 in GBC. E2F5 had been confirmed to aggravate tumor growth in vivo.
Conclusion:
E2F5 targeted by let-7d-5p facilitated cell proliferation, metastasis and immune escape in GBC through the JAK2/STAT3 pathway.
Insights
The oncogene E2F5 promotes gallbladder cancer (GBC) progression and poor prognosis. MicroRNA let-7d-5p suppresses E2F5, inhibiting GBC cell proliferation, metastasis, and immune escape via the JAK2/STAT3 pathway.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Gallbladder cancer (GBC) is a significant global cause of cancer mortality.
- E2F5 is a known oncogene implicated in various cancers, but its role in GBC was unexplored.
Purpose of the Study:
- To investigate the regulatory functions of E2F5 in GBC progression.
- To elucidate the molecular mechanisms underlying E2F5's role in GBC.
Main Methods:
- Gene expression analysis (qRT-PCR, Western blot, IHC).
- Cellular assays for proliferation (CCK-8, EDU), cytotoxicity (LDH), apoptosis, and immune cell infiltration (flow cytometry).
- In vivo tumor growth assays and luciferase reporter assays for molecular interactions.
Main Results:
- E2F5 expression correlates with poor prognosis in GBC patients.
- Overexpression of let-7d-5p suppressed GBC cell proliferation and metastasis by downregulating E2F5.
- E2F5 activates the JAK2/STAT3 signaling pathway, which is inhibited by let-7d-5p, contributing to GBC progression.
Conclusions:
- E2F5 promotes GBC cell proliferation, metastasis, and immune escape.
- let-7d-5p targets E2F5, thereby inhibiting GBC progression through the JAK2/STAT3 pathway.
Related Concept Videos
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:23Abnormal Proliferation
02:38Mitogens and the Cell Cycle
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...